Smoldering Myeloma

Discover more on Smoldering Myeloma with VJHemOnc

VJHemOnc presents The Smoldering Myeloma Channel, featuring the latest developments in this early form of myeloma directly from the experts, including novel investigational approaches, as well as insights into how to mitigate smoldering myeloma progression risk.

Watch a video, listen to our expert podcasts, and explore our latest congress coverage to stay informed on advances in the treatment and management of smoldering myeloma.

Controversies and perspectives on reaching and defining cure in myeloma 4:55
Controversies and perspectives on reaching and defining cure in myeloma
Xavier Leleu • 12 May 2023
The importance of treating patients with smoldering myeloma at high risk of progression to myeloma 3:48
The importance of treating patients with smoldering myeloma at high risk of progression to myeloma
Maria-Victoria Mateos • 12 May 2023
How do we define smoldering multiple myeloma? 0:56
How do we define smoldering multiple myeloma?
Eileen Boyle • 11 May 2023
Session highlights at COMy 2023: latest updates in myeloma disease biology & pathophysiology 3:27
Session highlights at COMy 2023: latest updates in myeloma disease biology & pathophysiology
Enrique Ocio • 11 May 2023
Diet-microbiome interactions in oncology and the importance of investigating this 5:45
Diet-microbiome interactions in oncology and the importance of investigating this
Urvi Shah • 24 Apr 2023
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma 1:51
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma
Sigurdur Kristinsson • 12 Dec 2022
Multivariate model to predict the need for bone marrow sampling in patients with MGUS 1:36
Multivariate model to predict the need for bone marrow sampling in patients with MGUS
Sigurdur Kristinsson • 12 Dec 2022
Smoldering myeloma: the challenges of ‘watch and wait’ versus early intervention 1:44
Smoldering myeloma: the challenges of ‘watch and wait’ versus early intervention
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM 3:25
Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
Identifying immune biomarkers of progression in patients with HR-SMM treated with immunotherapy 3:38
Identifying immune biomarkers of progression in patients with HR-SMM treated with immunotherapy
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
The role of PET-CT in the diagnosis and prognosis of multiple myeloma 2:09
The role of PET-CT in the diagnosis and prognosis of multiple myeloma
Noemí Puig • 11 Dec 2022
An insight into the prevalence of various subtypes of MGUS in the iStopMM study 1:42
An insight into the prevalence of various subtypes of MGUS in the iStopMM study
Sigurdur Kristinsson • 12 Dec 2022
GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM 1:28
GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM
Bruno Paiva • 11 Dec 2022
Understanding the risk of progression of smoldering myeloma to provide more personalized therapies 1:11
Understanding the risk of progression of smoldering myeloma to provide more personalized therapies
Irene Ghobrial • 11 Dec 2022
The potential of early treatment of SMM with immunotherapy 1:47
The potential of early treatment of SMM with immunotherapy
Irene Ghobrial • 11 Dec 2022
The PANGEA model: a novel dynamic model used to define disease progression in multiple myeloma 0:51
The PANGEA model: a novel dynamic model used to define disease progression in multiple myeloma
Irene Ghobrial • 11 Dec 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals